Literature DB >> 7661744

Diagnosis and successful medical treatment of Acanthamoeba keratitis.

G D'Aversa1, G A Stern, W T Driebe.   

Abstract

OBJECTIVE: To identify the methods that result in timely diagnosis and effective treatment of Acanthamoeba keratitis.
METHODS: We retrospectively reviewed the medical records of 12 consecutive patients whom we treated for culture-proved Acanthamoeba keratitis in 14 eyes.
RESULTS: Contact lenses were worn in 13 of 14 affected eyes and substandard methods were often used to care for them. The diagnosis was established in all patients by laboratory analysis of corneal scrapings; corneal biopsies were not required. Acanthamoeba organisms were identified on smears from 12 of 14 eyes with use of standard, nonfluorescent stains and recovered in culture from all patients by inoculating scrapings on nonnutrient agar overlaid with Escherichia coli. Eleven of 14 eyes were medically cured with a combination of antiamebic drugs, most commonly propamidine isethionate, neomycin sulfate, and clotrimazole. Topical corticosteroids were used in only one patient. Two of the three eyes that required therapeutic keratoplasty were not treated before surgery according to our usual protocol; the third required keratoplasty for treatment of a severe bacterial superinfection. Twelve of 14 eyes recovered 20/50 or better visual acuity. Bacterial superinfections were a serious problem, with a total of six superinfections occurring in three treated eyes.
CONCLUSION: With timely diagnosis and medical treatment with a combination of antiamebic drugs and avoidance of topical corticosteroids, most cases of Acanthamoeba keratitis can be cured, with an excellent prognosis for visual recovery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7661744     DOI: 10.1001/archopht.1995.01100090046021

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  9 in total

1.  Confirmatory evidence from 18S rRNA gene analysis for in vivo development of propamidine resistance in a temporal series of Acanthamoeba ocular isolates from a patient.

Authors:  D R Ledee; D V Seal; T J Byers
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

2.  [Acanthamoeba keratitis].

Authors:  N Szentmáry; L Daas; P Matoula; S Goebels; B Seitz
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

3.  Practice patterns and opinions in the treatment of acanthamoeba keratitis.

Authors:  Catherine E Oldenburg; Nisha R Acharya; Elmer Y Tu; Michael E Zegans; Mark J Mannis; Bruce D Gaynor; John P Whitcher; Thomas M Lietman; Jeremy D Keenan
Journal:  Cornea       Date:  2011-12       Impact factor: 2.651

Review 4.  Treatment of ocular inflammation in children.

Authors:  Sunil M Thadani; C Stephen Foster
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 5.  Acanthamoeba spp. as agents of disease in humans.

Authors:  Francine Marciano-Cabral; Guy Cabral
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

6.  Double-biguanide therapy for resistant acanthamoeba keratitis.

Authors:  Giulio Ferrari; Stanislav Matuska; Paolo Rama
Journal:  Case Rep Ophthalmol       Date:  2011-11-05

Review 7.  Acanthamoeba keratitis - Clinical signs, differential diagnosis and treatment.

Authors:  Nóra Szentmáry; Loay Daas; Lei Shi; Kornelia Lenke Laurik; Sabine Lepper; Georgia Milioti; Berthold Seitz
Journal:  J Curr Ophthalmol       Date:  2018-10-19

8.  The Effect of Anti-Amoebic Agents and Ce6-PDT on Acanthamoeba castellanii Trophozoites and Cysts, In Vitro.

Authors:  Lei Shi; Vithusan Muthukumar; Tanja Stachon; Lorenz Latta; Mohamed Ibrahem Elhawy; Gubesh Gunaratnam; Erika Orosz; Berthold Seitz; Albrecht F Kiderlen; Markus Bischoff; Nóra Szentmáry
Journal:  Transl Vis Sci Technol       Date:  2020-11-23       Impact factor: 3.283

9.  Topical Corticosteroids for Infectious Keratitis Before Culture-Proven Diagnosis.

Authors:  Koji Hirano; Hidenori Tanaka; Kumiko Kato; Kaoru Araki-Sasaki
Journal:  Clin Ophthalmol       Date:  2021-02-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.